PL355892A1 - 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor - Google Patents
4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitorInfo
- Publication number
- PL355892A1 PL355892A1 PL00355892A PL35589200A PL355892A1 PL 355892 A1 PL355892 A1 PL 355892A1 PL 00355892 A PL00355892 A PL 00355892A PL 35589200 A PL35589200 A PL 35589200A PL 355892 A1 PL355892 A1 PL 355892A1
- Authority
- PL
- Poland
- Prior art keywords
- carboxyamino
- tetrahydroquinoline
- ethyl
- crystal
- cetp inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16805199P | 1999-11-30 | 1999-11-30 | |
PCT/IB2000/001650 WO2001040190A1 (en) | 1999-11-30 | 2000-11-14 | 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
PL355892A1 true PL355892A1 (en) | 2004-05-31 |
Family
ID=22609901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL00355892A PL355892A1 (en) | 1999-11-30 | 2000-11-14 | 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP1246804A1 (xx) |
JP (1) | JP2003515592A (xx) |
KR (1) | KR20020058057A (xx) |
CN (1) | CN1402711A (xx) |
AP (1) | AP2002002531A0 (xx) |
AU (1) | AU1048801A (xx) |
BG (1) | BG106854A (xx) |
BR (1) | BR0015836A (xx) |
CA (1) | CA2392979A1 (xx) |
CO (1) | CO5271716A1 (xx) |
EA (1) | EA200200510A1 (xx) |
EC (1) | ECSP003792A (xx) |
EE (1) | EE200200277A (xx) |
GT (1) | GT200000199A (xx) |
HU (1) | HUP0203521A2 (xx) |
IL (1) | IL149097A0 (xx) |
IS (1) | IS6338A (xx) |
MA (1) | MA26845A1 (xx) |
MX (1) | MXPA02005354A (xx) |
NO (1) | NO20022558D0 (xx) |
OA (1) | OA12099A (xx) |
PA (1) | PA8506301A1 (xx) |
PE (1) | PE20010904A1 (xx) |
PL (1) | PL355892A1 (xx) |
TN (1) | TNSN00231A1 (xx) |
TR (1) | TR200201446T2 (xx) |
UY (1) | UY26454A1 (xx) |
WO (1) | WO2001040190A1 (xx) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
KR20040015746A (ko) | 2001-06-21 | 2004-02-19 | 화이자 프로덕츠 인크. | 콜레스테릴 에스테르 전달 단백질 억제제의 자가 에멀젼화제제 |
GT200200170A (es) | 2001-09-28 | 2003-05-23 | Preparacion de inhibidor de cetp anhidro | |
EP1920766B1 (en) * | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
WO2003063833A1 (en) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
PT1469833T (pt) * | 2002-02-01 | 2021-07-13 | Bend Res Inc | Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado |
KR100634195B1 (ko) | 2002-08-30 | 2006-10-16 | 니뽄 다바코 산교 가부시키가이샤 | 디벤질아민 화합물 및 그 의약 용도 |
BR0315041A (pt) | 2002-10-04 | 2005-08-16 | Millennium Pharm Inc | Métodos para inibir crth2 em um indivìduo que necessita inibição de crth2; composto; e composição farmacêutica |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
DE60323536D1 (de) | 2002-12-20 | 2008-10-23 | Pfizer Prod Inc | Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
MXPA05010456A (es) * | 2003-03-28 | 2006-03-21 | Pfizer Prod Inc | Compuestos de quinolina y quinoxalina. |
JP2007501218A (ja) | 2003-08-04 | 2007-01-25 | ファイザー・プロダクツ・インク | 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物 |
JP4773969B2 (ja) | 2003-10-08 | 2011-09-14 | イーライ リリー アンド カンパニー | 脂質代謝異常の治療ための化合物及び方法 |
AU2005233160B2 (en) * | 2004-04-13 | 2011-06-02 | Merck Sharp & Dohme Corp. | CETP inhibitors |
EA200700119A1 (ru) * | 2004-06-24 | 2007-10-26 | Эли Лилли Энд Компани | Соединения и способы лечения дислипидемии |
US20070149567A1 (en) * | 2004-09-23 | 2007-06-28 | Pfizer Inc | Quinoline compounds |
WO2006033001A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
CN101146776A (zh) | 2005-02-24 | 2008-03-19 | 米伦纽姆医药公司 | 治疗炎性疾病的pgd2受体拮抗剂 |
WO2006098394A1 (ja) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
CL2008000684A1 (es) | 2007-03-09 | 2008-08-01 | Indigene Pharmaceuticals Inc | Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica. |
US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
TWI450896B (zh) | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸 |
WO2016016157A1 (en) | 2014-07-30 | 2016-02-04 | F. Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
WO1998033775A1 (en) * | 1997-02-03 | 1998-08-06 | American Home Products Corporation | 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
-
2000
- 2000-11-09 CO CO00085285A patent/CO5271716A1/es unknown
- 2000-11-13 PA PA20008506301A patent/PA8506301A1/es unknown
- 2000-11-14 OA OA1200200158A patent/OA12099A/en unknown
- 2000-11-14 EP EP00971662A patent/EP1246804A1/en not_active Withdrawn
- 2000-11-14 IL IL14909700A patent/IL149097A0/xx unknown
- 2000-11-14 CN CN00816463A patent/CN1402711A/zh active Pending
- 2000-11-14 WO PCT/IB2000/001650 patent/WO2001040190A1/en not_active Application Discontinuation
- 2000-11-14 CA CA002392979A patent/CA2392979A1/en not_active Abandoned
- 2000-11-14 AP APAP/P/2002/002531A patent/AP2002002531A0/en unknown
- 2000-11-14 AU AU10488/01A patent/AU1048801A/en not_active Abandoned
- 2000-11-14 EA EA200200510A patent/EA200200510A1/ru unknown
- 2000-11-14 BR BR0015836-4A patent/BR0015836A/pt not_active IP Right Cessation
- 2000-11-14 HU HU0203521A patent/HUP0203521A2/hu unknown
- 2000-11-14 TR TR2002/01446T patent/TR200201446T2/xx unknown
- 2000-11-14 JP JP2001541875A patent/JP2003515592A/ja active Pending
- 2000-11-14 EE EEP200200277A patent/EE200200277A/xx unknown
- 2000-11-14 KR KR1020027006914A patent/KR20020058057A/ko not_active Application Discontinuation
- 2000-11-14 PL PL00355892A patent/PL355892A1/xx not_active Application Discontinuation
- 2000-11-14 MX MXPA02005354A patent/MXPA02005354A/es unknown
- 2000-11-28 UY UY26454A patent/UY26454A1/es not_active Application Discontinuation
- 2000-11-28 PE PE2000001267A patent/PE20010904A1/es not_active Application Discontinuation
- 2000-11-29 TN TNTNSN00231A patent/TNSN00231A1/fr unknown
- 2000-11-29 GT GT200000199A patent/GT200000199A/es unknown
- 2000-11-29 EC EC2000003792A patent/ECSP003792A/es unknown
-
2002
- 2002-04-12 IS IS6338A patent/IS6338A/is unknown
- 2002-05-27 MA MA26653A patent/MA26845A1/fr unknown
- 2002-05-29 NO NO20022558A patent/NO20022558D0/no not_active Application Discontinuation
- 2002-06-20 BG BG106854A patent/BG106854A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
CA2392979A1 (en) | 2001-06-07 |
PE20010904A1 (es) | 2001-09-10 |
WO2001040190A1 (en) | 2001-06-07 |
BG106854A (bg) | 2002-12-29 |
IS6338A (is) | 2002-04-12 |
KR20020058057A (ko) | 2002-07-12 |
JP2003515592A (ja) | 2003-05-07 |
EA200200510A1 (ru) | 2002-10-31 |
EP1246804A1 (en) | 2002-10-09 |
IL149097A0 (en) | 2002-11-10 |
HUP0203521A2 (hu) | 2003-02-28 |
MXPA02005354A (es) | 2002-12-11 |
CO5271716A1 (es) | 2003-04-30 |
GT200000199A (es) | 2002-05-23 |
UY26454A1 (es) | 2001-07-31 |
PA8506301A1 (es) | 2002-08-26 |
TR200201446T2 (tr) | 2002-11-21 |
NO20022558L (no) | 2002-05-29 |
CN1402711A (zh) | 2003-03-12 |
AP2002002531A0 (en) | 2002-06-30 |
AU1048801A (en) | 2001-06-12 |
MA26845A1 (fr) | 2004-12-20 |
ECSP003792A (es) | 2002-04-23 |
NO20022558D0 (no) | 2002-05-29 |
BR0015836A (pt) | 2002-08-06 |
OA12099A (en) | 2006-05-04 |
EE200200277A (et) | 2003-10-15 |
TNSN00231A1 (fr) | 2002-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL355892A1 (en) | 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor | |
IL173393A0 (en) | 4-carboxyamino-2- substituted-1,2,3,4- tetrahydroquinolines as cetp inhibitors | |
SI1114033T1 (en) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors | |
PL346830A1 (en) | 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors | |
GB9904103D0 (en) | Quinoline derivatives | |
ZA200007593B (en) | Quinoline Derivatives. | |
MXPA01013406A (es) | Compuestos inhibidores de vla-4. | |
ZA200203095B (en) | Biphenyl derivatives used as NHE-3 inhibitors. | |
IL150114A0 (en) | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | |
EP1140083A4 (en) | NEW CONNECTIONS | |
HK1047596A1 (en) | 14, 15-Beta-methylene substituted androgens | |
GB9920917D0 (en) | Novel process | |
GB9914583D0 (en) | Novel process | |
GB9901256D0 (en) | Novel compounds | |
SI1114031T1 (en) | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors | |
GB9915303D0 (en) | Novel process | |
CA88270S (en) | Sunglasses | |
CA88265S (en) | Sunglasses | |
CA88264S (en) | Sunglasses | |
GB9904105D0 (en) | Quinoline derivatives | |
ZA200109203B (en) | VLA-4 inhibitor compounds. | |
AU141768S (en) | Sunglasses | |
AU137566S (en) | Sunglasses | |
AU141771S (en) | Sunglasses | |
AU141767S (en) | Sunglasses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |